MAVS and cancer: It was reported that physiologic responses to radio-/chemotherapy converge on an antiviral program in recruitment of the RLR pathway by a sncRNA- (small nuclear RNAs U1 and U2-) dependent activation of RIG-I which commences cytotoxic IFN signaling, and suppression of MAVS conferred radioresistance in normal and cancer cells [11].